SynthesisEuropean urology2013
Metabolism of kidney cancer: from the lab to clinical practice.
Synthesis in European urology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 85 citations in OpenAlex.
- Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma.Scientific reports · 2016Trial
- Efficient extraction via titanium organic frameworks facilitates in-depth profiling of urinary exosome metabolite fingerprints.Analytical and bioanalytical chemistry · 2025Article
- Exploring the dual role of endoplasmic reticulum stress in urological cancers: Implications for tumor progression and cell death interactions.Journal of cell communication and signaling · 2024Review
- PDK1 promotes breast cancer progression by enhancing the stability and transcriptional activity of HIF-1α.Genes & diseases · 2024Article
- Enhancing breast cancer outcomes with machine learning-driven glutamine metabolic reprogramming signature.Frontiers in immunology · 2024Article
- Article
- Metabolic imaging with hyperpolarizedCancer · 2021Article
- Potential Clinical Value of Pretreatment De Ritis Ratio as a Prognostic Biomarker for Renal Cell Carcinoma.Frontiers in oncology · 2021Article
- Identification of a Novel Stem Cell Subtype for Clear Cell Renal Cell Carcinoma Based on Stem Cell Gene Profiling.Frontiers in oncology · 2021Article
- Comprehensive Transcriptomic Analysis of Critical RNA Regulation Associated With Metabolism and Prognosis in Clear Cell Renal Carcinoma.Frontiers in cell and developmental biology · 2021Article
- The Heterogeneity Metabolism of Renal Cell Carcinomas.Advances in experimental medicine and biology · 2021Article
- ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3.Theranostics · 2021Article
- The effect of a novel glycolysis-related gene signature on progression, prognosis and immune microenvironment of renal cell carcinoma.BMC cancer · 2020Article
- A cluster of metabolism-related genes predict prognosis and progression of clear cell renal cell carcinoma.Scientific reports · 2020Article
- The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma.Genes · 2019Review
- The 'Achilles Heel' of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy.Kidney cancer (Clifton, Va.) · 2019Review
- Dysregulation of Ketone Body Metabolism Is Associated With Poor Prognosis for Clear Cell Renal Cell Carcinoma Patients.Frontiers in oncology · 2019Article
- Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma.OncoTargets and therapy · 2019Article
- Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo.Cell metabolism · 2018Article
- Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Review
Corrections and comments
- Commented on by
Authors and funding
10 authors at 9 institutions in 2 countries.
Funding
Abstract
contextThere is increasing evidence for the role of altered metabolism in the pathogenesis of renal cancer.
objectiveThis review characterizes the metabolic effects of genes and signaling pathways commonly implicated in renal cancer. EVIDENCE ACQUISITION: A systematic review of the literature was performed using PubMed. The search strategy included the following terms: renal cancer, metabolism, HIF, VHL. EVIDENCE SYNTHESIS: Significant progress has been made in the understanding of the metabolic derangements present in renal cancer. These findings have been derived through translational, in vitro, and in vivo studies. To date, the most well-characterized metabolic features of renal cancer are linked to von Hippel-Lindau (VHL) loss. VHL loss and the ensuing increase in the expression of hypoxia-inducible factor affect several metabolic pathways, including glycolysis and oxidative phosphorylation. Collectively, these changes promote a glycolytic metabolic phenotype in renal cancer. In addition, other histologic subtypes of renal cancer are also notable for metabolic derangements that are directly related to the causative genes.
conclusionsCurrent knowledge of the genetics of renal cancer has led to significant understanding of the metabolism of this malignancy. Further studies of the metabolic basis of renal cell carcinoma should provide the foundation for the development of new treatment approaches and development of novel biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.